Viva Europa, a Land of Excellence in Research and Innovation for Health and Wellbeing

Auffray, Charles; Sagner, Michael; Abdelhak, Sonia; Adcock, Ian M.; Agustí, Àlvar; Amaral, M.D.; Antonarakis, Stylianos E.; Arena, Ross; Argoul, Françoise; Balling, Rudi; Barabási, Albert‐László; Beckmann, Jacques S.; Bjartell, Anders; Blomberg, Niklas; Bourgeron, Thomas; Boutron, Bertrand; Brahmachari, Samir K.; Bréchot, Christian; Brightling, Christopher; Cascante, Marta; Cesario, Alfredo; Charron, Dominique; Chen, Sai‐Juan; Chen, Zhu; Chung, Fan; Clément, K.; Conesa, Ana; Cozzone, Alain J.; Jong, Menno D. de; Deleuze, Jean‐François; Demotes, Jacques; Meglio, Alberto Di; Djukanović, Ratko; Doğrusöz, Uğur; Epel, Elissa S.; Fischer, Alain; Gelemanović, Andrea; Goble, Carole; Gojobori, Takashi; Goldman, Michel; Goossens, Herman; Gros, François; Guo, Yike; Hainaut, Pierre; Harrison, David J.; Hoffmann, Hans Jürgen; Hood, Leroy; Hunter, Peter; Jacob, Yves; Kitano, Hiroaki; Klingmüller, Ursula; Knoppers, Bartha Maria; Kölch, Walter; Koopmans, Marion; Lancet, Doron; Laville, Martine; Lehn, Jean‐Marie; Lévi, Francis; Lisistsa, Andrey; Lotteau, Vincent; Magnan, A.; Mayosi, Bongani; Metspalu, Andres; Moreau, Yves; N’Dow, James; Nicod, Laurent; Noble, Denis; Nogueira, Maria Manuela; Norrby‐Teglund, Anna; Nottale, Laurent; Openshaw, Peter; Ӧztürk, Mehmet “Dali”; Palkonen, Susanna; Parodi, Silvio; Pellet, Johann; Polašek, Ozren; Price, Nathan D.; Pristipino, Christian; Radstake, Timothy R D J; Raes, Martine; Roca, Josep; Rozman, Damjana; Sabatier, Philippe; Sasson, Shlomo; Schmeck, Bernd; Serageldin, Ismaïl; Simonds, Anita K.; Soares, Bento; Sterk, Peter J.; Superti‐Furga, Giulio; Supple, David; Tegnér, Jesper; Uhlén, Mathias; Werf, Sylvie van der; Villoslada, Pablo; Vinciguerra, Manlio; Volpert, Vitaly; Webb, Steve; Wouters, Emiel F.M.; Sanz, Ferrán; Nóbrega, Fernanda Silveira

doi:10.1097/pp9.0000000000000006

Cited by 6 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The technological barriers to introducing systems medicine into clinical practice are thus being overcome, as shown by the growing number of successful applications being presented at international conferences [39]. It is likely to take a generation to achieve the training of a new cohort of data scientists, medical doctors, health practitioners, and policy makers who are familiar with ‘advanced intelligence’ and who will work at the crossroads of human wisdom and machine performance, its application to healthcare and wellbeing, and its endorsement by the citizens through a world alliance of health and wellbeing [40].…”

Section: Ten Years Of Systems Medicine In Genome Medicine and Beyondmentioning

confidence: 99%

Ten years of Genome Medicine

Auffray¹,

Griffin

Khoury

et al. 2019

Genome Med

Self Cite

View full text Add to dashboard Cite

Section: Ten Years Of Systems Medicine In Genome Medicine and Beyondmentioning

confidence: 99%

Ten years of Genome Medicine

Auffray¹,

Griffin

Khoury

et al. 2019

Genome Med

Self Cite

View full text Add to dashboard Cite

“…6,7 The development of an open standard protocol enabling full compliance with personal data and privacy protection regulations will catalyze the transformation of healthcare delivery and the transition toward emphasis on management of well-being. 8 With the full deployment of systems medicine, through their monitor-ing over a long period of time, individuals will be provided with actionable recommendations to maintain their state of health and well-being, detect early events indicative of a risk or a transition to disease, enabling their management and reversal. The expectation is that expanding the monitoring from one to millions then billions of individuals over the next 25 years will trigger in one generation a reversal of the escalating costs of healthcare management, drug, and diagnostic development, providing the basis for a more cost-efficient and sustainable integrated healthcare system.…”

Section: What Will Be the Impact?mentioning

confidence: 99%

“…As in many other scientific and technological fields, the European Union has demonstrated its potential to play a leading role in the development of systems medicine. 8 The European Commission has invested very significant resources during the past decades in the development of systems biology and systems medicine, that is, through the Coordinating Action for the implementation of Systems Medicine in Europe (CASyM), which led to the formation of the European Association of Systems Medicine (EASyM; http://easym.eu), and a call for action to make sense of big data in health research. 9 The journal Systems Medicine will hopefully serve as a vehicle to echo the progress made in demonstrating the effectiveness of systems medicine principles, first in successful proof-of-concept pilot projects, then with deployment through renovated healthcare systems worldwide.…”

Section: What Will Be the Impact?mentioning

confidence: 99%

Interview with a Thought Leader on Systems Medicine—Charles Auffray, PhD

AuffrayCharles¹

2018

Systems Medicine

Self Cite

View full text Add to dashboard Cite

Why Does Systems Medicine Matter?Systems medicine represents the engine for progress in biomedicine and healthcare in the 21st century, and thus matters as much as chemistry and molecular biology did in the last two centuries of the past millennium, when there was a growing emphasis on the study of biological systems at the molecular level, which led to highly significant advances on our understanding of their structure and common functioning principles. In the process, it became increasingly clear that microorganisms, plants, animals, and humans are much more complex systems than those studied by classical chemistry and physics. To gain a deep understanding of the mechanisms underlying their behavior in physiology and disease, the analytical reductionist approach focusing on the identification of a limited number of elements was reaching its limits. It needed to be complemented with more global and integrative approaches based on systemic principles focusing on complex networks of interactions. Thus, over the first two decades of this century and millenium, systems biology approaches have been successfully developed using the mathematical and computational conceptual frameworks and tools developed in other scientific fields. Taking advantage of major technological and engineering advances, they now make it

show abstract

“…As elegantly elaborated by Topol, the use of big data in medicine is going to disrupt the medical system as we know it 2. Big data include both clinical data (eg, originating from electronic health records, healthcare system claims data or patient-generated data such as from apps), biological data issued from the development of molecular research leading to multi-omics complex molecular data,3 social data (eg, originating from social networks, Internet of Things, physical social connexions or economic data repositories), imaging data and environmental data (eg, urbanistic data, pollution or atmospheric conditions) 4 5. In parallel, artificial intelligence–based methodologies allowing computer systems to ‘learn’ from data (ie, progressively improve performance on a specific task without being explicitly programmed) are more and more accessible 6 7.…”

Section: Introductionmentioning

confidence: 99%

EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases

Gossec

Kedra

Servy³

et al. 2019

Ann Rheum Dis

Self Cite

View full text Add to dashboard Cite

BackgroundTremendous opportunities for health research have been unlocked by the recent expansion of big data and artificial intelligence. However, this is an emergent area where recommendations for optimal use and implementation are needed. The objective of these European League Against Rheumatism (EULAR) points to consider is to guide the collection, analysis and use of big data in rheumatic and musculoskeletal disorders (RMDs).MethodsA multidisciplinary task force of 14 international experts was assembled with expertise from a range of disciplines including computer science and artificial intelligence. Based on a literature review of the current status of big data in RMDs and in other fields of medicine, points to consider were formulated. Levels of evidence and strengths of recommendations were allocated and mean levels of agreement of the task force members were calculated.ResultsThree overarching principles and 10 points to consider were formulated. The overarching principles address ethical and general principles for dealing with big data in RMDs. The points to consider cover aspects of data sources and data collection, privacy by design, data platforms, data sharing and data analyses, in particular through artificial intelligence and machine learning. Furthermore, the points to consider state that big data is a moving field in need of adequate reporting of methods and benchmarking, careful data interpretation and implementation in clinical practice.ConclusionThese EULAR points to consider discuss essential issues and provide a framework for the use of big data in RMDs.

show abstract

Viva Europa, a Land of Excellence in Research and Innovation for Health and Wellbeing

Cited by 6 publications

References 9 publications

Ten years of Genome Medicine

Ten years of Genome Medicine

Interview with a Thought Leader on Systems Medicine—Charles Auffray, PhD

EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases

Contact Info

Product

Resources

About